Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.02 +1.23%

+$0.04 today

Market cap
$220.03M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 5.46M

Average 3.33M

Returns on capital

Cabaletta Bio, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-149.8%

avg -19.2%

ROIC

-123.8%

avg -31.0%

ROA

-101.7%

avg -2816.6%

Analysis

ROA is currently the strongest return metric at -101.7% versus its period average of -2816.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Steven A. Nichtberger

Co-Founder, Chairman, Chief Executive Officer & PresidentUSD 1.13M65——

David J. Chang FACR

Chief Medical OfficerUSD 807.14K63——

Gwendolyn K. Binder

President of Science & TechnologyUSD 773.96K51——

Anup Marda

Chief Financial OfficerUSD 548.2K48225.00K0.14%

Samik Basu

Chief Scientific Officer————

Aimee Payne

Co-Founder & Co-Chair of Scientific Advisory Board————

Michael C. Milone

Co-Founder & Co-Chair of Scientific Advisory Board————

Qing Sarah Yuan

Chief Technology Officer—55——

Michael Gerard

General Counsel & Secretary—46175.00K0.11%

Heather Harte-Hall

Chief Compliance Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

8

$296,188.53

Sells

0

$0.00

Net Transaction Value

+$296,188.53

Net buying

Most Active

Chang David J.

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jan 21, 26

Chang David J.

Direct

Buy$19.9K
Jan 21, 26

Binder Gwendolyn

Direct

Buy$24.8K
Jan 21, 26

Tomasello Shawn

Indirect

Buy$50.3K
Jan 21, 26

Gavel Steve

Direct

Buy$50.2K
Jan 21, 26

Bollard Catherine

Direct

Buy$10K
Jan 21, 26

Nichtberger Steven

Direct

Buy$100.8K
Jan 21, 26

Simon Mark

Direct

Buy$25.3K
Jan 21, 26

Gerard Michael

Direct

Buy$15K

Summary

Insiders reported 8 buys worth $296,188.53 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $296,188.53. Chang David J. was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A7 analysts
Net IncomeN/AN/AN/A
N/A7 analysts
EBITN/AN/AN/A
N/A7 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Cabaletta Bio, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CABA's management, answered from reported figures.

Who manages CABA?

Cabaletta Bio, Inc. (CABA) lists 10 active executives. The top listed executive is Samik Basu, Chief Scientific Officer.

Are CABA insiders buying or selling?

Recent insider activity shows net selling of $19.54M.